Trial reportDrug design, development and therapy2025
Efficacy of Intravenous Butorphanol for Preventing Epidural-Related Maternal Fever (ERMF) During Epidural Labor Analgesia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this research was to investigate whether intravenous low dose of butorphanol (1mg) at the onset of epidural analgesia (EA) can reduce the incidence of ERMF during labor. Patients and Methods: Four hundred and twenty-four women, aged 18 to 40 years, BMI <=30 kg/m Results: A total of 424 subjects (212 subjects in Butor group and 212 subjects in Con group) were included in the final analysis. There was a significant decrease for the incidence of maternal fever in Butor group compared to Con group (37.3% versus 48.6%, Conclusion: A low dose of butorphanol intravenously used at the onset of EA in women undergoing vaginal delivery could effectively reduce the incidence of ERMF. Butorphanol may serve as a potential intervention for preventing ERMF in future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.